Eighteen months after endorsing Eli Lilly and Incyte’s Olumiant in combination with Gilead’s Veklury for hospitalized COVID-19 patents, the FDA has given a full bless...

Incyte’s Opzelura is off to a promising launch, as indicated by a variety of metrics the company highlighted on Tuesday, but manufacturing troubles have threatened to...

Zosano Pharma’s headaches are intensifying. With the FDA again knocking back its transdermal migraine patch, the biotech has suspended its M207 program and made more ...

Aiming to make noise in oncology, Bayer is counting on prostate cancer drug Nubeqa as a potential blockbuster. On Tuesday, the company took a step toward that goal, ...

Biogen’s yearlong struggle with the controversial FDA approval and launch of Aduhelm has culminated in a deep overhaul reaching all the way to the CEO. Biogen CEO Mi...

Paxlovid’s first-quarter revenue haul may look slim, but plenty more sales are on the way in the next three months, Pfizer executives said on an earnings call Tuesday...

Watch out Johnson & Johnson, Bexson Biomedical is expanding its on-body ketamine delivery program to mental health conditions including treatment-resistant depres...

Contract manufacturer CordenPharma, recently tapped in a German push to earmark mRNA vaccine capacity, is getting a new owner. European private equity firm Astorg ha...

It’s the second year into Roche's Genentech’s five-year plan of increasing diversity and inclusion both within the company and out in the broader field of healthcare....